Drug Trial Radar · NCT04539639
Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
166
Actual
Start
Dec 2, 2020
Primary completion
May 19, 2022
Study completion May 19, 2022
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
JaktinibDrug
In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
JaktinibDrug
In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
JaktinibDrug
In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
placeboDrug
In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving at least a 50% Reduction in Eczema Area and Severity Index (EASI 50) from BaselineTime frame: At Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The second xiangya hospital of central south university
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.